A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Breast Cancer Research Foundation
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT00813956
First received: December 19, 2008
Last updated: September 14, 2013
Last verified: September 2013